Adverse reactions to pyrimethamine-sulfadoxine in context of AIDS

Multimodal AI-based risk stratification for distant metastasis in nasopharyngeal carcinoma.

ESMO open·2025

Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression.

ESMO open·2022

Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.

Oncogene·2014

Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-κB activation via a negative feedback loop.

Cell death & disease·2014

Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.

Oncogene·2014

Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.

Oncogene·2012

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Lancet (London, England)·2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Lancet (London, England)·2026

An autopsy case of diphenhydramine overdose with drug concentration data from multiple samples sites.

Forensic science, medicine, and pathology·2026

Chronic manganese exposure disrupts dopamine biosynthesis and amphetamine response in a mouse model of altered dopamine transport.

Neurotoxicology·2026

Discovery of novel dual μOR/σ1R ligands as potent analgesics with reduced tolerance liability and improved safety profiles.

European journal of medicinal chemistry·2026

Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor.

Dermatology and therapy·2026

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials.

Dermatology and therapy·2026

A Multicenter, Prospective Real-World Study of Simethicone-Activated Charcoal in Patients With Persistent Dyspeptic Symptoms Despite Acid Suppression (SIMAC Study).

JGH open : an open access journal of gastroenterology and hepatology·2026

Related Experiment Videos

Adverse reactions to pyrimethamine-sulfadoxine in context of AIDS

Related Concept Videos

Multimodal AI-based risk stratification for distant metastasis in nasopharyngeal carcinoma.

Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression.

Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.

Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-κB activation via a negative feedback loop.

Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.

Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

An autopsy case of diphenhydramine overdose with drug concentration data from multiple samples sites.

Chronic manganese exposure disrupts dopamine biosynthesis and amphetamine response in a mouse model of altered dopamine transport.

Discovery of novel dual μOR/σ1R ligands as potent analgesics with reduced tolerance liability and improved safety profiles.

Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor.

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials.

A Multicenter, Prospective Real-World Study of Simethicone-Activated Charcoal in Patients With Persistent Dyspeptic Symptoms Despite Acid Suppression (SIMAC Study).

Related Experiment Videos

Adverse reactions to pyrimethamine-sulfadoxine in context of AIDS

Related Concept Videos

Related Articles